RemSleep Holdings Inc. Annual Report - How They Did This Year

I’ve put together this guide to help you make sense of RemSleep Holdings Inc.’s latest annual report. My goal is to cut through the corporate jargon and help you understand how the business is actually doing, what’s working, and what you should watch.

1. What does this company do?

RemSleep is a medical device company focused on treating obstructive sleep apnea. Their flagship product, the "DeltaWave," is a specialized mask designed to be more comfortable than traditional CPAP gear. By addressing the common issue of patient discomfort, RemSleep aims to capture a portion of the $8 billion global sleep apnea market.

2. The Big Goal

The company is targeting a 10% share of the U.S. sleep apnea market. A major milestone was achieved in early 2026 when Medicare began covering the DeltaWave, allowing providers to bill for the device. The company is currently transitioning from research and development to a commercial focus, prioritizing the placement of the DeltaWave in sleep clinics and medical equipment supply networks.

3. Financial Health: The "Survival" Phase

The company is currently in a challenging financial position:

• Deepening Losses: The company reported a loss of $3.02 million in 2025, representing a 180% increase in losses compared to the $1.08 million lost in 2024.
• Revenue Shift: Revenue fell from $117,185 in 2024 to $16,721 in 2025. This decline reflects the company’s strategic decision to discontinue older product lines to focus exclusively on the DeltaWave.
• The Dilution Trap: Operations are being funded primarily through the issuance of new shares. In 2025, $400,000 of debt was converted into 123 million new shares. This expansion of the share count reduces the ownership percentage and potential value of existing shares.
• The "Going Concern" Warning: Auditors have issued a "going concern" warning, indicating uncertainty regarding the company’s ability to sustain operations over the next 12 months. With $214,514 in cash remaining, the company faces a significant liquidity challenge.

4. Major Wins and Challenges

• Operational Milestones: Beyond securing FDA clearance, the company has established a supply chain for the DeltaWave and successfully navigated the complex Medicare reimbursement process.
• The Debt Cycle: The company utilizes high-interest loans that allow lenders to convert debt into stock, often at a 30% to 50% discount. Lenders frequently sell these shares shortly after conversion, which can exert downward pressure on the stock price.
• Insider Compensation: In 2025, the CEO and COO were granted 2 million shares of preferred stock. These are convertible into 600 million common shares, representing a significant amount of potential future dilution for public shareholders.

5. What to Watch

• The Sales Ramp-Up: Monitor quarterly revenue reports for consistent growth. The company must demonstrate that the DeltaWave is being actively prescribed and adopted by medical providers.
• The Funding Lifeline: Keep an eye on SEC filings regarding new debt or equity offerings. Continued reliance on convertible loans is likely to impact the stock price.
• Shareholder Value: The most critical metric is whether revenue growth can outpace the issuance of new shares. If the company continues to issue shares faster than it generates sales, the value of your investment may be diluted further.

Final Thought for Investors: This is a high-risk, early-stage company currently in a "survival" phase. When evaluating your position, weigh the potential of the DeltaWave’s Medicare approval against the company’s immediate cash constraints and the ongoing risk of share dilution.